We are live on ! Find out more
IKT icon

Inhibikase Therapeutics
IKT

24 hedge funds and large institutions have $2.78M invested in Inhibikase Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

12% more capital invested

Capital invested by funds: $2.49M → $2.78M (+$292K)

9% more funds holding

Funds holding: 22 → 24 (+2)

1.16% less ownership

Funds ownership: 13.28% → 12.12% (-1.2%)

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
24
Holders Change
+2
Holders Change %
+9.09%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
1
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$135K
2
Citadel Advisors
Citadel Advisors
Florida
+$21.1K
3
CWM
CCG Wealth Management
California
+$17.5K
4
Millennium Management
Millennium Management
New York
+$14K
5
SG
StoneX Group
New York
+$11.7K

Top Sellers

Rank Fund Capital Flow
1
AC
Antara Capital
New York
-$299K
2
Renaissance Technologies
Renaissance Technologies
New York
-$85.3K
3
TRCT
Tower Research Capital (TRC)
New York
-$8.64K
4
SC
Shay Capital
New York
-$8K
5
RPCONE
Retirement Planning Company of New England
Rhode Island
-$4.86K

IKT Hedge Fund Activity: Q3 2022 in Review

24 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2022, worth a combined $2.78M — up 12% from $2.49M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new IKT positions and 3 closed out — a net gain of 2 holders — while 1 added to existing stakes and 4 trimmed.

The largest buyer was William Blair & Company, adding an estimated $135K. The largest seller was Antara Capital, exiting entirely with an estimated $299K sold.

  • 24 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2022, up from 22 in Q2 2022.
  • Funds reported $2.78M of Inhibikase Therapeutics stock for Q3 2022, up 12% quarter-over-quarter.
  • 5 funds opened new Inhibikase Therapeutics positions in Q3 2022 and 3 closed out, a net change of +2 holders.
  • The largest Inhibikase Therapeutics buyer in Q3 2022 was William Blair & Company, an estimated $135K added.
  • The largest Inhibikase Therapeutics seller in Q3 2022 was Antara Capital, an estimated $299K sold.

Based on aggregated 13F filings for Q3 2022.